Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in progressive multiple sclerosis
ISRCTN93303620Phase 3Completed
- Sponsor
- Dokumeds
- Start
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) comparing Masitinib with Placebo (2 arms). Primary endpoint: Time to 12-week confirmed EDSS progression. Started Mar 2022; status: completed.
02
Drugs
masitinib
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on ISRCTN93303620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN93303620.